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Background: Activation of leukocytes with concomitant release of myeloperoxidase (MPO) is considered an early event in acute coronary disease. 
Although several studies have investigated the diagnostic and prognostic performance of MPO plasma levels in patients with chest pain (CP) these 
studies were mainly monocentric and retrospective, of low size and lacked a cut-off value for MPO. Herein we prospectively assessed the diagnostic 
and prognostic properties of MPO as compared to high sensitive troponin I (sTNI) in patients admitted to the emergency room with CP.
Methods and Results: 1818 consecutive patients (mean age 61.4±13.5 y, 33.6% female) admitted for CP underwent determination of MPO, 
sTnI and BNP plasma levels at admission and 3 h and 6 h thereafter. A cut off for MPO was defined in 5000 population-based subjects. Baseline 
MPO plasma levels were elevated in patients with acute myocardial infarction and acute heart failure as compared to patients with unstable 
angina pectoris and non-cardiac chest pain. For all time-points accuracy of MPO was inferior to sTNI for predicting AMI. The sensitivity of MPO to 
diagnose AMI at presentation was 73.5% compared to 90.7% for sTNI and the specificity of MPO was 45.5% as opposed to 90.2% for sTNI. MPO was 
predictive of an increased risk for adverse events at 30 days and 6 months, which was additive to TnI.
Conclusion: The data reconfirm that circulating levels of MPO are elevated in patients with evolving AMI and acute heart failure, which further 
underscores the pathophysiological role of this enzyme in cardiovascular disease. However, the diagnostic information was not additive to that 
provided by sTNI, thus questioning the clinical value of MPO levels in CP-patients.
